Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

Non-small cell lung cancer (NSCLC) is one of the most efficient models for precision medicine in oncology. The most appropriate therapeutic for the patient is chosen according to the molecular characteristics of the tumor, schematically distributed between immunogenicity and oncogenic addiction. For...

Descripción completa

Detalles Bibliográficos
Autores principales: Denis, Marc G, Bennouna, Jaafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733376/
https://www.ncbi.nlm.nih.gov/pubmed/33324104
http://dx.doi.org/10.2147/CMAR.S218751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733376/
https://www.ncbi.nlm.nih.gov/pubmed/33324104
http://dx.doi.org/10.2147/CMAR.S218751

Ejemplares similares